Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture.
Publication/Presentation Date
8-1-1992
Abstract
Suramin is a polyanionic compound used clinically for the treatment of trypanosomiasis, which is known to inhibit the action of many protein factors in vitro. Transforming growth factor-beta (TGF-beta) is a multifunctional regulatory protein which inhibits the growth of renal cell carcinoma in culture. While suramin at 50-500 micrograms/ml had no significant effect on the growth of renal cell carcinoma in culture in our experiments, it did partially reverse the growth inhibition induced by TGF-beta in the two cell lines tested. This effect apparently is caused by suramin's direct interference with 125I-labeled TGF-beta's ability to bind to the cell, and not by any effect of suramin on the TGF-beta receptor. Furthermore, suramin dissociates TGF-beta bound to the cell with a t1/2 of less than 30 min. These results are consistent with those previously reported regarding suramin's interaction with other protein growth factors, and suggest that suramin may interact with the TGF-beta protein itself to inactivate it.
Volume
53
Issue
2
First Page
195
Last Page
198
ISSN
0022-4804
Published In/Presented At
Wade, T. P., Kasid, A., Stein, C. A., LaRocca, R. V., Sargent, E. R., Gomella, L. G., Myers, C. E., & Linehan, W. M. (1992). Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture. The Journal of surgical research, 53(2), 195–198. https://doi.org/10.1016/0022-4804(92)90034-w
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
1405609
Department(s)
Administration and Leadership
Document Type
Article